Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sante publique (Vandoeuvre-les-Nancy, France)·2026
Same author

FOXM1 expression is induced by the brain microenvironment and supports CRC brain metastatic adaptation.

Clinical & experimental metastasis·2026
Same author

Biselective remodeling of the melanoma tumor microenvironment prevents metastasis and enhances immune activation in mouse models.

Science translational medicine·2025
Same author

Trigeminal Neuralgia and Associated Hydrocephalus: Not a Mere Incidental Finding? A Case Report and Literature Review.

Pain medicine case reports·2025
Same author

Deep-Learning-Based Prediction of t(11;14) in Multiple Myeloma H&E-Stained Samples.

Cancers·2025
Same author

Primary Cavernous Sinus Yolk Sac Tumor in a Young Child.

Pediatric blood & cancer·2025

Related Experiment Video

Updated: Aug 28, 2025

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.8K

Digital PCR-Based Method for Detecting CDKN2A Loss in Brain Tumours.

Shlomo Tsuriel1, Victoria Hannes2, Asala Hasona2,3

  • 1Institute of Pathology, Tel-Aviv Sourasky Medical Center, 62431, Tel-Aviv, Israel. shlomots@tlvmc.gov.il.

Molecular Diagnosis & Therapy
|September 21, 2022
PubMed
Summary

A new digital PCR assay reliably detects CDKN2A loss in brain tumors, crucial for accurate diagnosis. This cost-effective method works with limited DNA and old samples, improving glioma classification.

More Related Videos

Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR
09:16

Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR

Published on: February 5, 2018

6.3K
Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
10:16

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

13.3K

Related Experiment Videos

Last Updated: Aug 28, 2025

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.8K
Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR
09:16

Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR

Published on: February 5, 2018

6.3K
Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
10:16

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

13.3K

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Genetics

Background:

  • CDKN2A is a critical tumor suppressor gene frequently lost in high-grade astrocytomas.
  • Loss of CDKN2A in low-grade gliomas can lead to aggressive tumor behavior.
  • Current methods for detecting CDKN2A loss are often impractical for routine pathology.

Purpose of the Study:

  • To develop and validate a digital PCR (dPCR) assay for reliable CDKN2A deletion detection.
  • To establish the assay's performance characteristics regarding tumor content and DNA quantity.
  • To assess the clinical utility of the dPCR assay in glioma diagnosis.

Main Methods:

  • Developed a dPCR assay quantifying CDKN2A gene copy number relative to a reference gene.
  • Determined assay sensitivity using varying tumor content and DNA amounts.
  • Validated the assay on clinical samples with known and unknown CDKN2A deletion status.

Main Results:

  • The dPCR assay demonstrated reliability in samples with >50% tumor content and >0.4 ng DNA.
  • Complete concordance was observed in the validation cohort.
  • Homozygous CDKN2A loss was detected in 16 previously uncharacterized gliomas.

Conclusions:

  • The dPCR assay provides a fast, cost-effective, and clinically reliable method for evaluating CDKN2A loss.
  • The assay's ability to use degraded DNA and small sample amounts makes it valuable for challenging cases.
  • This assay can significantly improve the accuracy of brain tumor diagnosis and classification.